Antibody antibody

Antigen: Antibody

Clonality: Polyclonal

Host: Rabbit

Application: Immunohistochemistry (IHC), Western Blotting (WB)

Catalog no.: ABIN350816

Additional Information

Swiss-Prot: Q01196

Immunogen: A synthetic peptide from the internal region of human Runt-related transcription factor 1 (Runx1, AML1, CBFA2) conjugated to an immunogenic carrier protein was used as the immunogen. The antigen is homologous in rat and mouse.

Format: Lyophilized

Description: FUNCTION: CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation. SUBUNIT: Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Isoform AML-1L can neither bind DNA nor heterodimerize. Interacts with TLE1 and THOC4. Interacts with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with MYST3 and MYST4. Interacts with SUV39H1, leading to abrogate the transactivating and DNA-binding properties of RUNX1. TISSUE SPECIFICITY: Highest levels in thymus, bone marrow and peripheral blood. Also known as: Runx1, Core-binding factor, alpha 2 subunit, CBF-alpha 2, Acute myeloid leukemia 1 protein, Oncogene AML-1, Polyomavirus enhancer-binding protein 2 alpha B subunit, PEBP2-alpha B, PEA2-alpha B, SL3-3 enhancer factor 1 alpha B subunit, SL3/AKV core-binding factor alpha B subunit, AML1, CBFA2.

Specificity: Appears to be specific for Runx1.

Application Details

Application Notes: IHC, WB. A dilution of 1 : 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user. Not yet tested in other applications.

Purity: whole serum

Storage: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Restrictions: For Research Use only

Images

IF on mouse cerebellum (4% PFA fixed, frozen section) at 1 : 500 dilution using Rabbit to antibody to internal region of Runx1 (AML1): whole serum (ABIN350816). DAPI counterstained.

IF on mouse cerebellum (4% PFA fixed, frozen section) at 1 : 500 dilution using Rabbit to antibody to internal region of Runx1 (AML1): whole serum (ABIN350816). DAPI counterstained appearing in blue.

IF on rat DRG (postnatal day 7) at 1 : 500 dilution using Rabbit antibody to human, rat, mouse Rabbit to antibody to internal region of Runx1 (AML1): whole serum (ABIN350816).

Publications

Publications: Daga, Tighe, Calabi: "Leukaemia/Drosophila homology." in: Nature, Vol. 356, Issue 6369, pp. 484, 1992 (PubMed).

Miyoshi, Shimizu, Kozu et al.: "t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, Issue 23, pp. 10431-4, 1992 (PubMed).

Levanon, Negreanu, Bernstein et al.: "AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization." in: Genomics, Vol. 23, Issue 2, pp. 425-32, 1995 (PubMed).

Zhu, Yeadon, Burden: "AML1 is expressed in skeletal muscle and is regulated by innervation." in: Molecular and cellular biology, Vol. 14, Issue 12, pp. 8051-7, 1994 (PubMed).

Bae, Yamaguchi-Iwai, Ogawa et al.: "Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1." in: Oncogene, Vol. 8, Issue 3, pp. 809-14, 1993 (PubMed).

Nucifora, Birn, Espinosa et al.: "Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis." in: Blood, Vol. 81, Issue 10, pp. 2728-34, 1993 (PubMed).

Ghozi, Bernstein, Negreanu et al.: "Expression of the human acute myeloid leukemia gene AML1 is regulated by two promoter regions." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 93, Issue 5, pp. 1935-40, 1996 (PubMed).

Zhang, Bae, Huang et al.: "A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells." in: Molecular and cellular biology, Vol. 17, Issue 7, pp. 4133-45, 1997 (PubMed).

Tahirov, Inoue-Bungo, Morii et al.: "Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta." in: Cell, Vol. 104, Issue 5, pp. 755-67, 2001 (PubMed).

Baeckstroem, Wolf-Watz, Grundstroem et al.: "The RUNX1 Runt domain at 1.25A resolution: a structural switch and specifically bound chloride ions modulate DNA binding." in: Journal of molecular biology, Vol. 322, Issue 2, pp. 259-72, 2002 (PubMed).